A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
CytomX Therapeutics (CTMX) is back in focus after reporting early Phase 1 expansion results for its EpCAM-targeting ADC, Varsetatug masetecan, in advanced colorectal cancer, alongside fresh earnings and a sizeable equity raise. See our latest analysis for CytomX Therapeutics. The latest EpCAM ADC data and the US$250.0m follow on equity raise have arrived after a sharp run, with a very large 1 year total shareholder return and a 3 year total shareholder return of 161.76%, even though the 30 day share price return is a 17.74% decline from the recent peak. If you are looking beyond a single biotech story and want more ideas linked to the rise of AI in healthcare, now is a good time to scan 35 healthcare AI stocks With CytomX now trading well below the recent offering price, despite multi year returns that are very large, the key question is simple: is the current valuation leaving meaningful upside on the table or already baking in future growth? Most Popular Narrative: 50.6%
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics (CTMX) had its price target raised by Piper Sandler from $10.00 to $12.00. They now have an "overweight" rating on the stock.MarketBeat
- CytomX Therapeutics (CTMX) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d)".MarketBeat
- CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.MarketBeat
- CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level [Seeking Alpha]Seeking Alpha
CTMX
Earnings
- 3/16/26 - Miss
CTMX
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- CTMX's page on the SEC website